TapImmune Inc. (NASDAQ:MRKR) saw a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 4,979,700 shares, a growth of 14.4% from the May 30th total of 4,354,000 shares. Currently, 18.3% of the shares of the company are sold short. Based on an average trading volume of 519,700 shares, the days-to-cover ratio is currently 9.6 days.
NASDAQ:MRKR traded down $0.04 during trading hours on Friday, reaching $8.79. The stock had a trading volume of 500,656 shares, compared to its average volume of 923,903. The company has a current ratio of 19.73, a quick ratio of 19.73 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average of $6.85. TapImmune has a 12-month low of $4.18 and a 12-month high of $10.92. The firm has a market capitalization of $399.80 million, a PE ratio of -5.26 and a beta of 0.34.
TapImmune (NASDAQ:MRKR) last released its earnings results on Thursday, May 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.05. As a group, equities research analysts expect that TapImmune will post -0.51 earnings per share for the current year.
A number of analysts recently commented on MRKR shares. Zacks Investment Research raised Icon from a “hold” rating to a “buy” rating and set a $157.00 price target for the company in a research report on Thursday, May 30th. ValuEngine raised YY from a “sell” rating to a “hold” rating in a research report on Friday, June 7th. Roth Capital raised Himax Technologies from a “neutral” rating to a “buy” rating and raised their target price for the stock from $4.00 to $5.00 in a research report on Thursday, May 30th. WBB Securities raised TapImmune from a “buy” rating to a “strong-buy” rating and set a $7.29 target price for the company in a research report on Friday, March 29th. Finally, Oppenheimer set a $32.00 target price on Iovance Biotherapeutics and gave the stock a “buy” rating in a research report on Wednesday, July 3rd. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $10.21.
An institutional investor recently raised its position in TapImmune stock. Riggs Asset Managment Co. Inc. boosted its stake in shares of TapImmune Inc. (NASDAQ:MRKR) by 68.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,919 shares of the company’s stock after acquiring an additional 18,650 shares during the quarter. Riggs Asset Managment Co. Inc. owned 0.10% of TapImmune worth $303,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 33.64% of the company’s stock.
TapImmune Company Profile
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Read More: When is a capital gain realized?
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.